Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only
“Global Radioimmunotherapy Market, Dosage, Price and Clinical Pipeline Outlook 2022” Report Highlights:
-
Need and Efficacy of Radioimmunotherapy
-
Components of Radioimuunotherapy
-
Clinical Status of Radioimmunotherapy in Various Cancer Therapy
-
Emerging Opportunities in the Radioimmunotherapy Segment
-
Patent, Dosage and Price Analysis
-
Antibodies in Radioimmunotherapy
-
Global Radioimmunotherapy Clinical Pipeline: 68 Drugs
-
Clinical Pipeline analysis by Phase
Cancer therapy is one of the most intensive areas of research globally. The severity and prevalence associated with cancer makes it one of the most feared ailments worldwide. Research conducted by various international organizations like the world health organization and the Centre for disease control clearly indicates the rising prevalence of cancer globally which is bound to be a major burden to the global healthcare sector in the coming decades . This has led to an increased demand of cancer therapeutics with high efficacy and less toxicity.
Out of all the existing cancer therapeutics being researched upon, immunotherapy is being anticipated as the most promising and viable segment of modern cancer therapeutics. Cancer Immunotherapy is the use of the body’s own immune system to treat cancer. Years of research has proved that the immune system can be trained to identify and eliminate particular cells from the body by giving suitable cues. This unique property of the immune system has widely been utilized to treat diseases by modulating immune responses.
It was however observed that the efficacy of cancer therapy significantly improved when combined with traditional radiation therapy which then gave rise to a new class of cancer therapy known as the cancer Radioimmunotherapy. The amalgamation of radiation therapy with immunotherapy proved to be a breakthrough method of cancer therapy with impressive results in cancers such as the Non- Hodgkin lymphoma; which was earlier considered to be a non-treatable cancer.
Ibritumomab tiuxetan and Iodine (131I) tositumomab are the two most popular Radio immunotherapeutics that received FDA Approval in the year 2002 and 2003 respectively. As of now only these two radio immunotherapeutics have been marketed globally for the treatment of non-Hodgkin lymphoma under the brandname Zevalin(Ibriumomab tiuxetan) and Bexxar(Tositumomab).
The excellent results obtained in cancer Radioimmunotherapy in the past and current research has led to the segment progressing rapidly in terms of both clinical and commercial aspects with increased attention from pharmaceutical and healthcare sectors around the world. While it has already been approved as a standard treatment for non Hodking Lymphoma and follicular lymphoma, it has yet to prove its clinical efficacy in other cancer types.
An insight into the clinical pipeline and current status of all the cancer types associated with Radioimmunotherapy presents an optimistic picture regarding its improvement with efficacy. With the advancement in science and technology, the Radioimmunotherapy segment is bound to progress at a rapid rate thus making it a promising cancer therapeutic of the future.
KuicK Research report on global Radioimmunotherapy aims at providing an in-depth analysis of the market with special emphasis on the Global market size, current market trend and factors affecting the future market growth. Additionally the report includes comparative price, dosage and therapy cost analysis of marketed Radioimmunotherapy drugs providing a detailed insight into the Radioimmunotherapy marketed products.
